A Phase 1/2 interventional study of Ibrutinib and MEDI4736 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-27.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · AbbVie.
Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 1/2, and was the 4th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →2 of the 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in Argentina, Australia, Austria and 10 more countries
Ages 18+
AbbVie
Ages 18+
By country, each count listing its studies:
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4
First in 2008; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 58 across the 10 interventional studies, 438 across the 2 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
2 of the studies in Lymphoma, Large B-Cell, Diffuse by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06667687AbbVieStudy to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | 2027-01 |
| NCT05512390AbbVieA Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate hematologic function:
Adequate hepatic and renal function:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
Drug: Ibrutinib · Drug: MEDI4736
In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
Drug: Ibrutinib · Drug: MEDI4736
Phase 1b/2 : Overall Response Rate of Number of Participants
The response criteria is measured based on the revised criteria for malignant lymphoma described by the International Working Group for NHL (Cheson 2014).
Time frame: From the date of first study treatment until progressive disease
Phase 1b/ 2: Duration of Response
Time frame: Time from the date of initial response to the date of disease progression or the date of death due to any cause, whichever occurs first.
Phase 1b/ 2: Progression-free Survival (PFS)
Time frame: first dose date of study drug (ibrutinib or MEDI4736) to the first documentation of disease progression
Phase 1b/2: Overall Survival
Time frame: First dose date of study drug (ibrutinib or MEDI4736) to the date of death due to any cause
Phamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib
Maximum observed plasma concentration of ibrutinib during the dosing interval on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)
Time frame: Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)
Pharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib
Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)
Time frame: Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)
Pharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib
Ibrutinib AUC0-24h calculated using linear trapezoidal summation after dosing from time 0 to 24 hours on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)
Time frame: Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)
Pharmacokinetics: Mean Terminal Elimination Half-Life (t1/2,Term) for Ibrutinib
Ibrutinib terminal elimination half-life associated with the terminal slope (λz) of the semi-logarithmic plasma concentration-time curve, calculated as 0.693/λz on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)
Time frame: Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)
Pharmacokinetics: Mean Peak Plasma Concentration (Cmax) for MEDI4736
Peak plasma concentration of MEDI4736 on Cycle 6 Day 1 (ibrutinib + MEDI)
Time frame: Cycle 6 Day 1 (collected 10 minutes after end of infusion)
Pharmacokinetics: Mean Trough Plasma Concentration (Ctrough) for MEDI4736
Trough plasma concentration of MEDI4736 on Cycle 6 Day 1 (ibrutinib + MEDI)
Time frame: Cycle 6 Day 1 (predose)
Pharmacokinetics: MEDI4736 Accumulation Ratio for Cmax
Accumulation ratio from Cycle 6 Day 1 to Cycle 1 Day 1 for Cmax for MEDI4736
Time frame: Cycle 6 Day 1 (collected 10 minutes after end of infusion)
Pharmacokinetics: MEDI4736 Accumulation Ratio for Ctrough
Accumulation ratio from Cycle 6 Day 1 to Cycle 1 Day 1 for Ctrough for MEDI4736
Time frame: Cycle 6 Day 1 (predose)
Bruton Tyrosine Kinase (BTK) Occupancy
BTK occupancy
Time frame: ibrutinib Lead-in Day 6 or 7 pre-dose
Pharmacodynamics of Ibrutinib in Subjects With Relapsed or Refractory Lymphomas
BTK occupancy
Time frame: Cycle 3 Day 1 Pre-dose
Pharmacodynamics of MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Detectable Free Serum PD-L1 level
Time frame: Cycle 3 Day1 Pre-dose
| Milestone | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Started | 27 | 34 |
| Completed | 5 | 4 |
| Not completed | 22 | 30 |
The response criteria is measured based on the revised criteria for malignant lymphoma described by the International Working Group for NHL (Cheson 2014).
| Participants | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Phase 1b/2 : Overall Response Rate of Number of Participants | 7 | 8 |
| Months | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Phase 1b/ 2: Duration of Response | 11.3 (8.3 to NA) | NA (2.5 to NA) |
| Months | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Phase 1b/ 2: Progression-free Survival (PFS) | 10.2 (4.7 to 13.1) | 2.6 (1.5 to 4.4) |
| Months | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Phase 1b/2: Overall Survival | NA (23.6 to NA) | 5.1 (3.7 to 10.1) |
Maximum observed plasma concentration of ibrutinib during the dosing interval on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)
| ng/mL | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Lead-In Day 6/7 | 196 ± 245 | 140 ± 117 |
| Cycle 3 Day 1 | 155 ± 102 | 183 ± 101 |
Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)
| hour | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Lead-In Day 6/7 | 1.95 (0.750 to 4.00) | 2.01 (0.930 to 6.00) |
| Cycle 3 Day 1 | 2.00 (1.00 to 6.05) | 2.07 (1.00 to 4.97) |
Ibrutinib AUC0-24h calculated using linear trapezoidal summation after dosing from time 0 to 24 hours on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)
| ng*h/mL | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Lead-In Day 6/7 | 1078 ± 1013 | 936 ± 691 |
| Cycle 3 Day 1 | 1096 ± 748 | 1606 ± 901 |
Ibrutinib terminal elimination half-life associated with the terminal slope (λz) of the semi-logarithmic plasma concentration-time curve, calculated as 0.693/λz on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)
| hour | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Lead-In Day 6/7 | 5.35 ± 2.16 | 6.43 ± 1.92 |
| Cycle 3 Day 1 | 6.14 ± 1.96 | 5.27 ± 1.21 |
Peak plasma concentration of MEDI4736 on Cycle 6 Day 1 (ibrutinib + MEDI)
| ug/mL | Phase 1b/ 2: Follicular Lymphoma & DLBCL Expansion Cohort |
|---|---|
| Pharmacokinetics: Mean Peak Plasma Concentration (Cmax) for MEDI4736 | 388 ± 14.1 |
Trough plasma concentration of MEDI4736 on Cycle 6 Day 1 (ibrutinib + MEDI)
| ug/mL | Phase 1b/ 2: Follicular Lymphoma & DLBCL Expansion Cohort |
|---|---|
| Pharmacokinetics: Mean Trough Plasma Concentration (Ctrough) for MEDI4736 | 207 ± 12.8 |
Accumulation ratio from Cycle 6 Day 1 to Cycle 1 Day 1 for Cmax for MEDI4736
| ratio | Phase 1b/ 2: Follicular Lymphoma & DLBCL Expansion Cohort |
|---|---|
| Pharmacokinetics: MEDI4736 Accumulation Ratio for Cmax | 1.90 ± 0.51 |
Accumulation ratio from Cycle 6 Day 1 to Cycle 1 Day 1 for Ctrough for MEDI4736
| ratio | Phase 1b/ 2: Follicular Lymphoma & DLBCL Expansion Cohort |
|---|---|
| Pharmacokinetics: MEDI4736 Accumulation Ratio for Ctrough | 3.31 ± 0.8 |
BTK occupancy
| BTK % occupancy | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Bruton Tyrosine Kinase (BTK) Occupancy | 77.6 ± 8.4 | 91.2 ± 3.4 |
BTK occupancy
| BTK % occupancy | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Pharmacodynamics of Ibrutinib in Subjects With Relapsed or Refractory Lymphomas | 83.1 ± 9.4 | 94.4 ± 3.1 |
Detectable Free Serum PD-L1 level
| pg/mL | Phase 1b/ 2: Follicular Lymphoma Expansion Cohort | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort |
|---|---|---|
| Pharmacodynamics of MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | 18.4 | NA |
Collected over All AEs, whether serious or non-serious, are documented in the source documents from the time the signed and dated ICF is obtained until 30 days following the last dose of ibrutinib and 90 days following the last dose of MEDI4736.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b/2: Follicular Lymphoma Expansion Cohort: | 6/27 (22.2%) | 10/27 (37%) | 27/27 (100%) |
| Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort: | 24/34 (70.6%) | 23/34 (67.6%) | 33/34 (97.1%) |
| Event | Phase 1b/2: Follicular Lymphoma Expansion Cohort: | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort: |
|---|---|---|
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/27 | 6/34 |
| Atrial FibrillationCardiac disorders | 1/27 | 3/34 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/27 | 3/34 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 2/27 | 0/34 |
| PyrexiaGeneral disorders | 0/27 | 2/34 |
| PneumoniaInfections and infestations | 0/27 | 2/34 |
| Urinary tract infectionInfections and infestations | 0/27 | 2/34 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/27 | 2/34 |
| NeutropeniaBlood and lymphatic system disorders | 1/27 | 1/34 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/27 | 0/34 |
| Event | Phase 1b/2: Follicular Lymphoma Expansion Cohort: | Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort: |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 16/27 | 16/34 |
| FatigueGeneral disorders | 12/27 | 16/34 |
| Upper respiratory tract infectionInfections and infestations | 12/27 | 3/34 |
| Oedema peripheralGeneral disorders | 7/27 | 13/34 |
| NauseaGastrointestinal disorders | 9/27 | 12/34 |
| NeutropeniaBlood and lymphatic system disorders | 6/27 | 11/34 |
| Decreased appetiteMetabolism and nutrition disorders | 8/27 | 11/34 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/27 | 6/34 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 6/27 | 3/34 |
| HeadacheNervous system disorders | 6/27 | 1/34 |
| Age, Categorical(Participants) | Phase 1b/2: Follicular Lymphoma Expansion Cohort: | Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort: | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 15 | 34 |
| >=65 years | 8 | 19 | 27 |
| Age, Continuous(years) | Phase 1b/2: Follicular Lymphoma Expansion Cohort: | Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort: | Total |
|---|---|---|---|
| Mean | 57 ± 11.88 | 61.2 ± 15.15 | 59.3 ± 13.85 |
| Sex: Female, Male(Participants) | Phase 1b/2: Follicular Lymphoma Expansion Cohort: | Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort: | Total |
|---|---|---|---|
| Female | 10 | 13 | 23 |
| Male | 17 | 21 | 38 |
| Race (NIH/OMB)(Participants) | Phase 1b/2: Follicular Lymphoma Expansion Cohort: | Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort: | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 23 | 32 | 55 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Region of Enrollment(participants) | Phase 1b/2: Follicular Lymphoma Expansion Cohort: | Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort: | Total |
|---|---|---|---|
| United States | 27 | 34 | 61 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2015, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2019, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab
Lymphoma, Large B-Cell, Diffuse →